Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Common Equity: 2017-2025

Historic Common Equity for Puma Biotechnology (PBYI) over the last 9 years, with Sep 2025 value amounting to $115.3 million.

  • Puma Biotechnology's Common Equity rose 62.15% to $115.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $115.3 million, marking a year-over-year increase of 62.15%. This contributed to the annual value of $92.1 million for FY2024, which is 72.38% up from last year.
  • Latest data reveals that Puma Biotechnology reported Common Equity of $115.3 million as of Q3 2025, which was up 10.07% from $104.7 million recorded in Q2 2025.
  • In the past 5 years, Puma Biotechnology's Common Equity registered a high of $115.3 million during Q3 2025, and its lowest value of -$10.9 million during Q3 2021.
  • Over the past 3 years, Puma Biotechnology's median Common Equity value was $53.4 million (recorded in 2023), while the average stood at $66.2 million.
  • As far as peak fluctuations go, Puma Biotechnology's Common Equity crashed by 2,311.04% in 2021, and later spiked by 983.40% in 2022.
  • Over the past 5 years, Puma Biotechnology's Common Equity (Quarterly) stood at -$2.4 million in 2021, then surged by 983.40% to $21.6 million in 2022, then spiked by 147.33% to $53.4 million in 2023, then skyrocketed by 72.38% to $92.1 million in 2024, then spiked by 62.15% to $115.3 million in 2025.
  • Its last three reported values are $115.3 million in Q3 2025, $104.7 million for Q2 2025, and $97.1 million during Q1 2025.